- Horizon Discovery’s Diagnostics business unit to provide custom molecular reference standards for on-going assay validation programs
Cambridge, UK 30 December 2014: Horizon Discovery Group plc (LSE:HZD) (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced that its Diagnostics Business Unit (Horizon Diagnostics) has entered into an agreement to provide molecular reference standards to a leading molecular diagnostics company.
Under the terms of the agreement, Horizon will be paid USD 810,000 (approximately GBP 520,000) to provide reference standards in the form of custom genomic DNA (gDNA) reagents to support assay validation efforts. The revenue, to be recognised over approximately six months of FY2014 and FY2015, represents the largest single diagnostic reagent order received by the division since its inception.
Dr. Paul Morrill, Senior Vice President, Reagent Products of Horizon Discovery Group plc, commented: “This significant deal demonstrates the value our molecular reference standards are having in assay development and in insuring that those assays are reliable and robust. That Horizon was chosen by a leading diagnostics company to provide support for their internal projects further demonstrates our leadership in this field.”